Introduction
============

The coexistence of carotid and coronary artery disease (CAD) is a challenge to cardiologists, vascular and cardiothoracic surgeons, and neurologists. Patients with coexistent narrowing of carotid and coronary arteries represent a particularly high-risk group and to date there has been no consensus with regard to their management. Carotid endarterectomy in these patients is associated with an increased incidence of perioperative myocardial infarction ([@b4]), and coronary artery bypass grafting is accompanied by an elevated risk of neurological injury ([@b29]).

Epidemiological data
====================

While in a general adult population the prevalence of carotid stenosis approaches 4% ([@b40]), in patients with coronary artery disease it can reach 30%--70% ([@b31]; [@b21]; [@b35]; [@b38]). For those undergoing coronary artery bypass grafting, the prevalence of \>50% narrowing of at least one internal carotid artery is thought to be around 20%, and \>70% carotid stenosis is found in 2%--12% of cases ([@b50]; [@b11]).

Carotid artery disease as a marker of increased risk of cardiovascular events
=============================================================================

Carotid artery disease, even in its preclinical stage (intima-media thickness \[IMT\] ≥1 mm and non-obstructive \[\<50%\] carotid plaques), has been associated with CAD and an increased risk of cardiovascular events.

Intima-media thickness
----------------------

For the far (posterior) wall of the carotid artery, this index can be easily measured by ultrasound as the distance between the leading edge of the luminal echo (first bright line) and the leading edge of the media-adventitia echo (second bright line). For the near (anterior) wall, IMT is measured as the distance between the trailing edge of the first bright line and the trailing edge of the second bright line ([@b45]; [@b25]). In clinical trials, IMT has been used as a surrogate end point for evaluating the progression of atherosclerosis ([@b9]; [@b46]).

The use of IMT for assessment of cardiovascular event risk has, however, a number of limitations. Although IMT has been shown to be a strong predictor of incident myocardial infarction in overall population aged ≥55 years ([@b54]), and there is a good correlation between increased IMT and the presence of CAD, IMT is not a good predictor of its extent and severity and cannot predict the absence of significant CAD. Furthermore, IMT does not appear to have predictive value in populations with high prevalence of CAD, or in younger age groups where the prevalence is low ([@b2]; [@b21]). Therefore, the American Heart Association Prevention V Conference ([@b17]) did not recommend routine IMT measurements in patients with low or high risk of cardiovascular disease, but stated that this may be appropriate in patients at intermediate risk of CAD (based on Framingham risk assessment). This means that if in a patient at intermediate risk of coronary event (6%--20% risk in 10 years) the carotid IMT of ≥1 mm is detected, he/she may be stratified as a high-risk patient and receive high-risk treatment accordingly.

The assessment of IMT in various laboratories is not standardized. In some studies only the common carotid artery IMT has been considered ([@b21]; [@b8]), in others, along with the common carotid artery IMT, the IMT in carotid bifurcation (bulb), and internal carotid artery has been measured ([@b25]). Thereafter the results have been either averaged ([@b20]; [@b56]) or the greatest IMT values have been used for analysis ([@b25]; [@b7]). These methodological differences limit the interpretation of results. Moreover, a relatively large proportion of variation in repeated measurements over time is likely to be due to measurement error. Most studies suggest, however, that the common carotid artery is the preferable site for the measurement of IMT because it is tubular and can be aligned perpendicular to the transducer beam. Reproducibility and yield of the common carotid artery IMT is therefore superior to that of IMT of the carotid bifurcation or internal carotid artery ([@b24]; [@b6]).

Recent consensus ([@b53]) concluded that there is no need "to treat" IMT values or to monitor IMT values in individual patients. IMT measurements are not recommended to predict events on an individual level, but may be used in clinical trials as a surrogate end point on a group level. The recommended standardized methods for IMT measurements are supposed to improve the power of studies incorporating IMT values and to facilitate the merging of databases for meta-analyses.

Carotid plaques
---------------

Carotid plaques in various studies have been defined either as distinct areas "with an IMT exceeding twice that of neighboring sites" ([@b21], p 64) or "focal widenings of the vessel wall of \>50% relative to adjacent segments" ([@b22], p 2873), or a "lesion with a focal IMT of 1.1 mm or more, with a localized protrusion of the vessel wall into the lumen ([@b23], p 1178). In another study, a cut-off point of 1.3 mm was used for a focal thickening of the IMT complex to be considered as a plaque ([@b30]). According to the consensus statement ([@b53]), a plaque is defined as a focal structure that encroaches into the arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value or demonstrates a thickness of ≥1.5 mm as measured from the media-adventitia interface to the intima-lumen interface. Obstructive plaques (causing \>50% lumen diameter narrowing) cause blood flow acceleration at the stenosis site and a peak systolic velocity \>125 cm/sec in the internal carotid artery is an indicator of its hemodynamically significant narrowing ([@b15]). The presence of obstructive carotid plaques is associated with increasing risk of cerebrovascular events by atheroembolism, as the severity of the stenosis increases ([@b41]), and increased risk of cardiac death and myocardial infarction ([@b21]).

The risk associated with the presence of non-obstructive carotid plaques remains a controversial problem. Like IMT, these plaques reflect the overall atherosclerotic burden, and, as compared with IMT, better predict cardiovascular death and nonfatal myocardial infarction ([@b21]).

The risk of ischemic events related to carotid plaques is also much associated with their histological morphology. Plaque echogenicity as assessed by B-mode ultrasound has been shown to correlate with histological findings. Echolucent plaques consist of a thin fibrous echogenic cap overlying a lipid core with high macrophage content and, sometimes, zones of hemorrhage. When the cap is thinner than 5--10μ it may not be detected by ultrasound. Echogenic plaques consist of dense fibrous tissue and their echogenicity increases with increasing amounts of collagen. The presence of calcifications results in high echoes in corresponding areas with acoustic shadowings ([@b14]; [@b10]). Several classifications have been proposed to group carotid plaques according to their appearance on ultrasound ([Table 1](#tbl1){ref-type="table"}).

###### 

Ultrasonographic classifications of carotid plaques

  [@b16] and [@b13]                                                              [@b28]                      [@b48]                                               [@b10]
  ------------------------------------------------------------------------------ --------------------------- ---------------------------------------------------- -------------------------
  Type 1: predominantly echolucent with a thin echorich cap                      Soft (low level echoes)     Heterogeneous (high, medium, and low level echoes)   Ecolucent heterogeneous
  Type 2: dominantly echolucent lesions with small areas of echogenicity         Soft (low level echoes)     Heterogeneous (high, medium, and low level echoes)   Ecolucent heterogeneous
  Type 3: dominantly echogenic lesions with small (\<25%) areas of echolucency   Dense (high level echoes)   Heterogeneous (high, medium, and low level echoes)   Intermediate
  Type 4: echorich homogeneous                                                   Dense (high level echoes)   Homogeneous (medium or high level echoes)            Echorich homogeneous
  Type 5: plaques with acoustic shadowing caused by calcification                Calcified                   Homogeneous (medium or high level echoes)            Echorich homogeneous

Echolucent and heterogeneous plaques are described as the most vulnerable, rupture-prone lesions and have been associated with neurovascular symptoms and an increased risk of ischemic stroke ([@b47]; [@b18]; [@b39]; [@b52]). Echogenic plaques are most frequently associated with asymptomatic status ([@b1]). In a general population, the ratio of subjects with echolucent plaques to subjects with echogenic plaques is approximately 1:2 ([@b27]; [@b57]). Ecolucent plaques dominate in patients with symptomatic carotid disease, while asymptomatic patients usually have echogenic plaques ([@b51]). It should be noted, however, that carotid plaques are dynamic structures that change in composition over a period of time. Patients with recent symptoms are more likely to have echolucent plaques compared with patients with earlier symptoms ([@b10]).

In patients evaluated for chest pain and in those with acute coronary syndromes, there is a stepwise increase in the number with carotid disease with the increasing severity of CAD ([@b31]; [@b36]). A gradual increase in the proportion of echogenic carotid plaques was observed with the increase of the extent of CAD, while the proportion of echolucent carotid plaques remained unchanged ([Figure 1](#fig1){ref-type="fig"}) ([@b36]). This could reflect the natural development of more organized and calcified plaques in more advanced stages of atherosclerosis.

![Distribution of echolucent and echogenic carotid plaques according to the extent of coronary artery disease in the entire study population. Data adapted from [@b36]. **Abbreviations:** VD, vessel disease. [note]{.smallcaps}: black bars = echogenic carotid plaque group; white bars = echolucent carotid plaque group.](vhrm0102-131-f1){#fig1}

Recently, [@b38] classified carotid plaques as complex (those with irregular surface and/or heterogeneous echogenicity involving \>50% of the plaque area, including echolucent, mobile, and ulcerated plaques) and simple (plaques with smooth surface and a homogeneous hyperechoic structure involving \>50% of the plaque area). They demonstrated that complex carotid plaques are more prevalent in patients with unstable angina pectoris compared with patients with stable angina. As in a general population, the ratio between complex and simple carotid plaques in patients with CAD is approximately 1:2 ([@b38]); however, this ratio seems to grow with the increasing instability of patients due to the increased prevalence of complex carotid plaques ([@b38]). These results are complementary to the recent findings, which showed that acute coronary syndrome patients with multiple complex coronary plaques had more either echolucent or echogenic carotid plaques and carotid calcifications compared with patients who only had a single complex coronary plaque ([@b32]).

The prognostic relevance of ultrasound characteristics of carotid plaques for cardiovascular events is somewhat controversial. In one of the studies it was demonstrated that in patients undergoing endarterectomy because of \>50% or \>70% stenosis, the echolucency of the removed carotid plaques was associated with the risk of myocardial infarction and stroke combined ([@b37]). Another study showed that a combined end point of death, myocardial infarction, or stroke was significantly more frequent in hypertensive patients with echolucent carotid plaques compared with comparable patients with echo-rich carotid plaques. Moreover, the multiple risk intervention program was beneficial in patients with echolucent carotid plaques, but not in those with echogenic carotid plaques ([@b49]). Finally, [@b23] showed that echolucent carotid plaques predict coronary plaque complexity and the development of future coronary complications in patients with stable coronary artery disease. These studies, however, have some potential limitations. In the studies of [@b37] and [@b49], the combined end points were used, and therefore, conclusions with regard to cardiovascular events only could not be made. [@b23] compared patients with echolucent carotid plaques with patients without carotid disease and patients with echogenic carotid plaques taken together. Such combination masked the risk associated with echogenic carotid plaques. Moreover, the overall prevalence of carotid disease in stable CAD patients was very high (79%), as was the prevalence of echolucent carotid plaques (52%).

Conversely, it has been shown that in patients with acute coronary syndromes, either echogenic or echolucent carotid plaques are associated with lower event-free survival regardless of the treatment strategy (conservative treatment or myocardial revascularization) ([@b36]). However, the presence of echogenic carotid plaques appeared to be an independent predictor of cardiac death and nonfatal myocardial infarction in these patients. Echogenic carotid plaques, when associated with complex coronary lesions, were associated with a particularly poor long-term event-free survival ([@b36]). One of the links that explain the associations between echogenic carotid plaques and cardiac events might be increased arterial stiffness, which is observed in patients with echogenic carotid plaques ([@b57]) and which, by itself, is associated with adverse cardiovascular outcomes ([@b5]). Echogenic carotid plaques might also reflect the total burden of calcium and of atherosclerosis, including that of the coronary arteries ([@b42]). The amount of coronary calcium and the fast progression of coronary calcifications, revealed by electron beam tomographic and multidetector scanning, has been previously associated with a greater risk of cardiovascular events ([@b44]; [@b33]). Finally, carotid calcifications may also reflect a diffuse coronary disease. The extent of non-obstructive atherosclerotic lesions has been found to be a strong predictor of coronary events, independent of severity and the number of flow-limiting coronary lesions ([@b3]).

These data, however, do not completely resolve the existing controversy. Recent observations have suggested that inflammation may be a possible link between coronary and carotid plaque instability ([@b38]). Complex carotid plaques were detected more frequently in patients with CAD and elevated serum C-reactive protein (\>3 mg/L) compared with patients with normal C-reactive protein levels. It may be that the degree of generalized inflammation, as reflected by C-reactive protein level, determines the echolucent plaque instability and the associated adverse outcomes. Moreover, higher interleukin-6 and high-sensitivity C-reactive protein levels have been recently shown to be associated with lower echogenicity of carotid plaques ([@b55]). These data are in contradiction with the previous studies, which failed to demonstrate significant associations between echolucency of carotid plaques and acute phase reactants such as fibrinogen ([@b34]), C-reactive protein, orsomucoid ([@b19]), and intracellular adhesion molecule-1 ([@b43]). Although the acute phase reactants reflect the general inflammation and may not be significantly modulated by changes in the carotid arteries ([@b19]), we suggest that echolucent plaques in patients with inflammation might have a different risk than echolucent plaques without evident signs of inflammation. In support of this, there is increasing evidence that acute phase reactants, especially C-reactive protein, are not just the markers of inflammation but also active participants of the formation process of atherosclerotic plaques ([@b58]; [@b12]).

Clinical implications
=====================

A high prevalence of carotid disease in patients with CAD and the associated risks imply that screening for carotid atherosclerosis should be considered in all patients with diagnosed CAD. The detection of carotid disease may modify treatment strategy of these patients; eg, more aggressive medical therapy in case of subclinical carotid atherosclerosis, combined coronary and carotid surgery for patients with critical stenoses in both territories, and staged operations.

Conclusions
===========

1.  Intima-media thickness may be used for cardiovascular risk assessment in patients at intermediate risk of CAD.

2.  The presence of carotid plaques is associated with an increased risk of cardiovascular events in patients with CAD, regardless of the treatment strategy (medical therapy alone or myocardial revascualrization).

3.  The prognostic relevance of ultrasound characteristics of carotid plaques in patients with CAD, possibly in association with inflammatory markers, needs to be further clarified.
